Compare Davita Inc (DVA) vs Levi Strauss & Co. (LEVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Levi Strauss & Co. — how do they compare? Davita Inc trades at $178.35 (market cap $11.72B), while Levi Strauss & Co. trades at $22.7 (market cap $9.09B). The key difference: Davita Inc is the larger of the two by market cap, and Levi Strauss & Co. pays a 2.71% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | LEVI | |
|---|---|---|
Market Cap | $11.72B | $9.09B |
Sector | Health | Consumer Cyclical |
52-Week High | $240.96 | $25.53 |
52-Week Low | $103.87 | $17.92 |
Enterprise Value | $24.44B | $10.40B |
Dividend Yield | — | 2.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $183.77, up 1.72% today, with a mixed technical picture showing bearish moving averages but bullish oscillators. The company reported strong Q2 2026 earnings of $4.02 per share, beating estimates, driven by volume growth. Revenue reached $13.64 billion in 2025, with a net income margin of 6.05%. Analyst consensus is a Buy with a $232.25 price target, though technical signals are bearish overall.
The outlook for DVA is cautiously optimistic, supported by earnings beats and volume growth, but risks include reimbursement pressure and high debt levels. The stock offers potential upside to the consensus target, yet investors face headwinds from margin compression and technical bearishness.
Levi Strauss (LEVI) trades at $24.4, up 0.39% on the day, with a bullish fundamental backdrop including strong earnings beats and a 77.78% analyst buy rating. The stock shows a bearish technical signal overall, with neutral RSI readings and key resistance at $25. Recent news highlights a cybersecurity breach disclosed on August 7, 2026, but the company's direct-to-consumer digital strategy continues to drive growth.
Outlook remains positive with a consensus price target of $27.88, implying 14.3% upside, supported by robust profitability and raised 2026 guidance. Risks include recent cybersecurity issues, tariff pressures, and execution challenges in a competitive apparel market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Levi Strauss & Co.
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →
